LIAFLine October 2006
19th Annual Remembrance Ball
NEWSLETTER OF THE LONG ISLAND ALZHEIMER’S FOUNDATION
INSIDE THIS ISSUE... • International Conference on Alzheimer's Disease • Sisters In Research • Remembrance Ball • Kurt Fuchel Memoir • Long Island Elite Gives • Sixth Annual Candlelighting • Memory Paddle Challenge • Outstanding Service Awards Luncheon
Drugs in Alzheimer's Disease, 2006 by Dmitry Goldgaber, Ph.D., Dr.Sci., Scientific Adviser, LIAF e are constantly bombarded by reports of breakthroughs in Alzheimer's disease. Let us take a look at 2 Associated Press reports from November 13, 1986: DRUG MAY TREAT ALZHEIMER'S STUDY FINDS PILLS IMPROVE MEMORY This was the first report on the use of tetrahydroaminoacrine, or THA, also known as tacrine in a small group of patients. Tacrine became the first drug approved for treatment of AD in the US. It is not used now because of serious side effects and because a new generation of drugs was developed without these side effects.
W
GENE THAT MIGHT PLAY KEY ROLE IN ALZHEIMER'S DISEASE FOUND. The article described the first report on the identification of the gene that encoded amyloid (Abeta) peptide. This peptide forms aggregates in the brains of patients with AD that are considered the hallmarks of the disease. The identification of the APP gene and determination of its location on chromosome 21 was a pivotal event in the
research on AD. It led to the development of various strategies and drugs that are in progress now and that will most likely lead to the treatment of the disease. Today we can tell which story reported a real breakthrough, but 20 years ago it was difficult to tell. What are we going to do in this confusing world of announcements and predictions? We follow thoroughly the fundamental research that is conducted in academic research labs and in labs of pharmaceutical and biotech companies, without losing hope that one or more of these research groups will succeed in bringing us a true and effective treatment. Scientists investigate the fundamental processes and mechanisms that lead to AD. They identify the targets and develop the rationale for drug design. And finally, scientists develop drugs. This is true not only for the drugs that are in the early stages of development in the labs, but also true for the drugs that are being tested in human trials and for drugs currently given to patients with AD. Some drugs currently used by patients with AD are based on scientific discoveries that were made a
long time ago. The drugs that are undergoing trials now are based on more recent findings. The future drugs that will treat AD will be based on experiments that are being conducted today in research labs. The pharmaceutical industry has been late in this process and only lately, in the last decade, committed a significant amount of money and resources to the field. In the meantime, the amount of money that our government made available for academic researchers in the AD field has decreased dramatically. Funding has worsened significantly in the last few years. If we want to have real breakthroughs in AD, we have to change the current status quo and dramatically increase the amount of money that is available for AD researchers. All drugs that are used or being developed for AD can be divided into 2 broad categories. One is Alzheimer's specific and the other is Alzheimer nonspecific. The first category is based on our knowledge of processes that are unique for AD, while the drugs in the second category were developed for conditions Continued on page 3
LIAFLine
Executive Director’s View Hello Friends! LIAF is busy planning for November and National Alzheimer's Disease Awareness Month. We will honor several LIAF "Angels" at our Remembrance Ball -- individuals and a corporation who have supported us over many years -- speaking on our behalf at workshops and conferences, organizing special panel discussions, providing web information, supporting our events with team work and funding. We thank Ginny Belling, RN, MS, Madelyn Dubiner, Phyllis Ettinger, MA, Med, Blaine Greenwald, MD, Arnie Levy, MD, David Okrent Esq., CPA, and Verizon Communications, Inc. We appreciate you everyday! Please join us as we honor loved ones at our Candle Lighting at the Bristal Assisted Living in North Hills on November 8. Then on November 16, we will gather to reflect on 2006 at our Annual Meeting and plan for 2007. As we prepare for Thanksgiving and the Holidays, we are grateful to all who helped LIAF this year -- Eisai staff who helped run our summer BBQ, Olympians Kathy Colin and Dru van Hengel who paddled around LI, our public and private sector donors and grantors. It takes many to help LIAF provide programs and services. Please be a part by making a donation during our Annual Appeal in December or at anytime during the year. Your contributions make assistance to our clients and families possible. Best regards,
Founder’s Corner Dear Friends, I am writing this column with the anticipation of reading it myself. This past July a major conference took place in Madrid, Spain and our science advisor, Dr. Dmitry Goldgabor was there on our behalf. The press releases were exciting coming from the event but I am most interested in Dr. Goldgabor’s take on the newest developments in his article in this newsletter. Everyday there is news in the world of Alzheimer’s disease but few developments become tantamount to an actual benefit for the future, but we only need one really great one to change our lives. To all of the researchers from around the world who traveled to Spain to share their knowledge, my gratitude. Congratulations to this year’s Honorees for the Remembrance Ball on November 3rd. I am delighted to be Dinner Chairperson and look forward to seeing many of you there. This event is our most successful in terms of dollars raised and we really need the support of all of our friends. It has been a tough year as I see more and more people affected by dementia who are my peers. The stigma is still so intimidating and it saddens me when someone is ashamed of having difficulty with their memory. Alzheimer’s disease is no different from any other disorder; we need to treat it early and aggressively. Most of all, we need to keep social and not shut out family and friends. Enjoy our beautiful Fall season and create good memories. My best,
Please designate LIAF as your United Way charity.
LIAFLine The Long Island Alzheimer’s Foundation, Inc. Leslie Gonzalez, Editor 5 Channel Drive, Port Washington, NY 11050 (516) 767-6856 Fax: (516) 767-6864 e-mail: info@liaf.org Internet: www.liaf.org
LIAFLine is the newsletter of the Long Island Alzheimer’s Foundation, Inc. (LIAF). It is supported entirely by contributions and is intended for caregivers, service providers and anyone interested in Alzheimer’s Disease or the Foundation. Articles, news items, correspondence, or other materials of interest are welcomed for publication consideration.
® 2006 The Long Island Alzheimer's Foundation, Inc Material in LIAFLine may be reproduced, with proper reference to source. Any statements of fact and opinion are the responsibility of the authors herein and do not imply an opinion or endorsement on the part of The Long Island Alzheimer's Foundation, Inc.
2
October 2006
LIAFLine
Drug Discoveries Dr. Dmitri Goldgaber
...Continued from page 1
other than AD and are being tested and used in AD because of their beneficial or perceived beneficial effects. The usefulness of all drugs in both categories has to be vigorously tested. The discovery of the amyloid gene (APP) 20 years ago opened a new era in AD research. It identified new targets and led to the development of new AD specific drugs that are currently being used in human trials. We now know that amyloid peptide, or Abeta peptide, is a fragment of APP and is produced by two stepwise cuts of APP. The enzymes that cut APP are called secretases. Abeta peptide is produced not only in patients with AD but also in healthy people. However, in patients Abeta forms various toxic aggregates or clumps. Most current approaches aim to decrease or eliminate Abeta and /or Abeta aggregates. One approach is to target secretases that cut Abeta from APP. This is being achieved by employing inhibitors of secretases. Identification and characterization of these enzymes took many years and the efforts of many research groups. Inhibitors of these secretases have been found and are being tested. This approach has been successful in experiments in cell cultures and in animals. Several companies are already testing various inhibitors of secretases in Phase II trials. Another very promising approach is immunotherapy, i.e. the use of immune system against Abeta peptide. This can be achieved by either stimulation of the patient's immune defense by vaccination with Abeta peptide, socalled active immunization. This approach has been tried and produced some serious side effects. However, because of its
enormous promise, researchers are trying to modify it in order to significantly decrease side effects. Infusion of antibodies against Abeta peptide is another method that is called passive immunization. It can be achieved by the generation of specific antiAbeta antibody or by infusion of human immunoglobulin that contain such antibody. All 3 methods are currently being tested. Promising results with specific anti-Abeta antibodies were recently reported by Wyeth and Elan. In Madrid, Dr. Norman Relkin from the Cornell Medical Center reported encouraging results in a small group of AD patients treated with immunoglobulins that were obtained from healthy donors. Small improvements disappeared when the treatment was stopped and returned when it was resumed. A very original approach to elimination of Abeta aggregates from the brain was presented at the 10th International Conference on Alzheimer's Disease (ICAD) in Madrid this summer by Dr. Beka Solomon from Tel Aviv University. She used linear phages, small viruses that infect bacteria but are harmless for animals. The structure of these phages resembles the structure of Abeta aggregates and therefore they might interfere with the formation of the aggregates. In experiments in animals the Israeli scientists demonstrated clearance of Abeta depositions in response to intranasal treatment by phages. Alzheimer non-specific drugs were either developed for conditions other that AD, or developed for conditions that are present in AD and in a variety of other diseases. It is surprising, but true, that the most prescribed medicine that
is used today with some effectiveness in AD, Aricept, is based on the discovery of cholinergic deficit that affects the function of neurons. The discovery was made by Peter Davis and independently by 2 other groups of scientists about 30 years ago. Tacrine was the first in the line of drugs that somewhat delayed the progression of AD. Newer drugs such as galantamine, donepezil, and rivastigmine have similar efficacy and fewer side effects. Memantine is a drug that was used for several decades to treat various neurological conditions because it may protect the brain from neuronal death. Memantine was given to patients with AD and several studies demonstrated a small beneficial effect of the drug. While none of these drugs cures AD, they cause symptomatic improvement. These drugs, especially Aricept, became a gold standard in clinical research. In many clinical trials reported in Madrid researchers used these drugs to compare the effects of newly developed drugs. Cholesterol-lowering drugs, or statins, have been shown to lower the risk of developing of AD. Several years ago there were encouraging reports on the use of statins in model systems that mimic AD. Unfortunately, these laboratory findings were not Continued on page 8
LIAF ANNUAL MEETING The Long Island Alzheimer’s Foundation will hold its Annual Meeting on Thursday, November 17, 2005 at 6 PM at LIAF Headquarters, 5 Channel Drive, Port Washington. The public is invited. To RSVP, call LIAF at 516-767-6856. October 2006
3
LIAFLine
Research
An Interview with ADRC Volunteers By Kathleen Van Dyk Sisters Adele Arpadi and Mollie Vogel first volunteered to participate in the Alzheimer's Disease Research Center in November of 1985, when the center itself was one year old. Since then, they have volunteered for over 15 different ADRC research studies and are consulted annually for ADRC related research. Both graciously agreed to provide this interview to share some of their experiences. KV: Why did you first start participating with ADRC 20 years ago? AA: We did it because friends of ours had done it at New York Hospital and found it was a very interesting kind of procedure. We found that it was the beginning of our volunteering for other kinds of studies. We find it interesting, enjoyable and educational, for us. MV: Yes. KV: Did you think at the time that you would be participating for this long? MV and AA: (laughing) No! AA: No, once or twice, and then we'd all be done. Then they kept calling us back, and we thought, 'ok, we'll go.' We had a third friend come with us and…[she dropped out] but we thought, 'well, this is kind of interesting we'll keep going. Especially in the initial years there were so many [different studies]…eye tests and others, and what does that have to do with Alzheimer's? KV: Why have you continued? MV: I think, personally, it's that we do see differences in ourselves, and we want confirmation that it's nothing.
4
October 2006
KV: And you're both planning to participate for the rest of your lives? MV: Yes. AA: Yes. As long as we can get there, that might become an issue… MV: (both laughing) I mean, you know, we're participating longer than we expected because we're living longer than we expected to be. KV: You've participated in several different studies, is there one in particular that sticks out and why? AA: Well, I think what interested me most was the scopolamine one, when we became aware of the… MV: the effects of Alzheimer's… AA: …the devastating effects that dementia has on people. I think when you begin to hold up a fork and ask us to name it, it's kind of devastating. That's when you begin to understand the devastation. MV: Actually, I think the injection one was the least interesting. I found the diet one to be interesting; we had to stay overnight for that one too. KV: Did either of you have any reservations about joining the ADRC? MV: No. AA: No, because it was noninvasive. I was very nervous [during] the first few interviews, until I began to say, 'but they're not testing me to see how smart I am.' I approached it the way you do an exam: “Am I going to do well?” But then I took two interviews and I said, 'but that's not what the interview is all about, so relax.' KV: Why have you encouraged others to participate?
MV: Because it's fun, it really is. AA: Yes. And we'll continue; we'll try to recruit more people. It's painless. I will never forget one of those early tests, we had to identify people from another name. They showed us a picture of 'Rebel Without a Cause' and we had to say, 'James Dean.' The worst of it for me was that they showed me an instrument, and I will never forget this: I said, 'They use it for checking heart and blood pressure… it's not a sphygmomanometer...' I said, 'I can't think of the name.' and I walked out of there embarrassed! Those were the hard ones, it wasn't enough to remember what it was, but you needed to name it. MV: Yeah, but you know what? We would go through these tests and… we did not ridicule. If you held up this [holds up a pencil] and said, 'what is this,' it was painful because we knew there were some people who couldn't name it. KV: What do you hope will come out of the research you're volunteering for? MV: A diagnosis of Alzheimer's before death, an early diagnosis. AA: Yes, and medications. ❍
19th Annual
Remembrance Ball Friday, November 3, 2006 • The Garden City Hotel 7 PM Cocktails – 8 PM Dinner and Dancing – Black Tie
Honoring Our LIAF Angels Corporate Angel
Blaine S. Greenwald, MD, Director, Geriatric Medical Center, The ZuckerHillside Hospital/Long Island Jewish
Arnold P. Levy, MD David R. Okrent, Viginia Belling, Long Island College Esq., Law Offices of RN, MS Hospital David R. Okrent Senior Placement Services
Yes, I wish to place a journal ad.
Reservation Form Please indicate your level of support. ■ ■ ■ ■
Yes, I wish to attend the Ball. Please reserve ______ seats at $600 per person Please reserve ______ tables of 10 at $6000 per table I am unable to attend, but please accept my donation of $——————
Name Company
State
Zip
■ Enclosed is the text for my ad; please design the copy for me. (I have included a company logo if needed).
Home/Office Phone Fax Total Amount Enclosed:
Exp. Signature
■ Enclosed is my camera-ready ad (perfect copy, ready for print). Camera-ready ads must be submitted as velox, film, a clean computer printout, on disk, or sent via e-mail.
$——————
Enclosed is my check for $—————— Charge my: ■ Visa ■ MC ■ Amex Card #
■ Front or back inside cover (subject to availability) (7 3/16" w X 9 1/2" h) . . . . . . . . . . . . . . . .$10,000 ■ Gold Page (7 3/16" w X 9 1/2" h) . . . . . . . . . .$3,000 ■ Silver Page (7 3/16" w X 9 1/2" h) . . . . . . . . .$2,000 ■ Full Page (7 3/16" w X 9 1/2" h) . . . . . . . . . . .$1,500 ■ Half Page (7 3/16" w X 4 3/4" h) . . . . . . . . . . . .$750 ■ Quarter Page (3 5/8" w X 4 3/4"h) . . . . . . . . . . .$400 ■ Supporter Recognition . . . . . . . . . . . . . . . . . . . .$125 Journal Ad instructions: ■ Please reuse or update last year’s ad if possible; enclosed is the ad with the revisions.
Address City
Phyllis Ettinger, MA, Madelyn Dubiner MED Caregiver Council Royal Health Care Member Services
■ Discover
For professional ads, please use a 133 line screen, at 300 dpi. NO BORDERS PLEASE. Journal has predesigned boarders. All camera-ready ads must be received by Friday, October 13, 2006.
Please mail completed form and ad, along with payment, to: LIAF, 5 Channel Drive, Port Washington, NY 11050. Checks should be made payable to: L.I. Alzheimer’s Foundation.
LIAFLine
Client’s View
Recollections By Kurt Fuchel he subject of memory has fascinated me for a long time, especially now that I am losing mine. I had been steadily writing my memoirs when my writing came to a stop. I had occasional episodes of forgetfulness - “senior moments,” I told myself. When I confessed to a “senior moment” to my doctor during a physical, he shrugged and said it was normal “for a man your age.” I really hate that phrase. I decided to undergo some tests at Columbia Presbyterian Hospital. A psychologist noted my biographical facts and figures, and then ran through the usual list of questions to see if I was “oriented” in time and space. Yes - I knew the day of the week, the city I was in, and the name of the President. I could not correctly place the four previous presidents, but I remained unperturbed, as politics is not a topic that greatly interests me. I was then turned over to another psychologist, a small mildmannered man, who for two hours assailed me with one test after another. “Repeat the number I'm going to give you”, he ordered. “1-3-2-5.” “1325”, I snapped back. “1-7-8-4-6-3”. Again I repeated it, but slower. “Now repeat the digits in reverse order.” Whoops! That's not so easy; I had to close my eyes and visualize the number once the number of digits reached 6 or 7. He read a list of about twenty words and asked me to repeat the ones I remembered; I got about 70% right. The next test involved fitting the pieces of a cut up picture together in a sensible way, while he timed me; in fact he seemed to look at his large stop watch, which he
T
6
October 2006
caressed lovingly, more often than he looked at me. He then asked me which words from the previous list I still remembered; my recollection was down to about 20%. Very disturbing. I consoled myself with the realization that, although I could not remember all the words, I could accurately define every one. I was asked whether I would be willing to participate in a research project designed to determine which patients are likely to decline slowly, and which ones would deteriorate rapidly. I was assured that the risk to my health was very small; every 6 months I would be tested, and radioactive tracer injected which would allow the researchers to see how my brain behaves under a “workload.” I spent 35 years of my life working for a research organization, so I volunteered. Six months later, I came in for the “follow up.” There had clearly been some progress; instead of a psychologist with his list of words, picture cards and stop watch, there was now a laptop computer to run the tests, with very little human intervention. In each hand I held a button, the right hand one for “Yes,” the left one for “No.” The words and patterns I was expected to remember appeared on the computer's screen. I kept losing track of whether I was supposed to remember the word flashed at me, or to recall whether it was in the previously shown list. We then moved to the Positive Emission Tomography (PET) machine. I was strapped into a tube, which was then inserted into the belly of the PET machine. Now timing became critical. When injected in my vein, the radioactive material would make visible, for a
brief time, how my brain functions when it's really doing work, not just idly dreaming. “Let's go!” The laptop computer sprang to life, and I held tightly to the two switches in my hands. Sweat was running into my eyes, as I concentrated on each question, the words and the strange curves flashed before my eyes. Once or twice, I knew the right answer, but pressed the wrong button. The day was grueling. Two research teams interviewed my wife and I at length, after which I was upgraded to “moderate stage” Alzheimer's disease. We both really expected that, but hoped the loss would not have been so devastating. I took stock. True, my long-term future was clouded, but at the moment I felt I was functioning at about 90 percent. Kurt Fuchel of Rocky Point, Long Island, was one of thousands rescued during the British government's “Kindertransport” prior to World War II. His narrative was featured in the documentary “Into the Arms of Strangers” (Academy Award, 2001) and subsequently honored by the British Royal Family. An engineer and mathematician, he retired from Brookhaven Labs in 1995 after 35 years of service. His work included the lab's computerization. His work included the computerization of BNL. This memoir was submitted by Hyman A. Enzer, Prof-Emeritus of Hofstra University, with permission from Kurt's wife, Concetta Fuchel. ❍
Holiday Gifts Available! Ornament Sale • Plush Toy Sale True Love Wall Art • Framed Works Books, Pins, Media Call 516-767-6856
Happenings
LIAFLine
Elite Generosity!!! he Long Island Alzheimer’s Foundation recently accepted a $5,000 check from the Long Island Elite (LIE), an organization dedicated to fostering the growth and development of Long Island’s business professionals under the age of 40. Founded in 2002, the LIE accomplishes its objectives through programs, activities and special events that support the region’s not-for-profit community. The $5,000 was raised through the Long Island Elite’s Arabian Nights Masquerade, held June 15, 2006 at the Oheka Castle in Cold Spring Hills, NY. The Masquerade event, held annually, raises funds and awareness for multiple charities. Members of the business community enjoyed a festive evening of food, cocktails, dancing, prizes and entertainment. Honored were LIAF Trustee Thomas J. Killeen, Esq., Partner, Farrell Fritz, P.C., as Mentor of the Year; and Andrew Jacono, MD, of The New
T
Long Island Alzheimer’s Foundation Presents Sixth Annual
Commemorative Candle Lighting Ceremony
York Center for Facial Plastic & Laser Surgery, as Contemporary Award Recipient. Other nonprofit beneficiaries included the Education and Assistance Corporation (EAC), The Maurer Foundation for Breast Health Education, the Nassau Coalition Against Domestic Violence and the National Foundation for Human Potential.
Pictured left to right are Dawn Strain, President and Founder, Long Island Elite; Thomas J. Killeen, Esq., Honoree; Leslie Gonzalez, Director of Communications, LIAF; Andrew Jacono, MD, Honoree; and Tracey Anastas, Waldner’s Business Environments; and Christie Pennino, Green Street Financial Group. ❍
Wednesday, November 8, 2006 The Bristal at North Hills 99 South Service Road North Hills Reception & Outdoor Candle Lighting 7:00 PM – 9:00 PM ~ Rain or Shine ~
In Recognition of National Alzheimer’s Disease Awareness Month Join us in lighting a Flame of Hope for the thousands presently coping with Alzheimer’s disease and as a memorial tribute to those who struggled with the disease in the past.
October 2006
7
LIAFLine
Drug Discoveries Dr. Dmitri Goldgaber
...Continued from page 3
reproduced in patients. However, the research on the role of cholesterol in AD continues and a number of research groups presented their studies in Madrid. During last few years several studies provided evidence for a link between diabetes and AD. While the exact relationship between these 2 diseases is not clear, the relationship suggested that diabetes drugs might be helpful to patients with AD. Several reports presented at the 10th ICAD further supported this idea. Analysis of data collected by the Veteran Administration showed that diabetic patients that used the anti-diabetes drugs thiazolidinediones (TZDs), including pioglitazone and rosiglitazone, were less likely to develop AD. Moreover, GlaxoSmithKline recently published preliminary data of a small clinical trial of rosiglitazone, a diabetes drug approved by the FDA, showing that the drug was helpful to patients who had no apolipoprotein E4 allele, a known genetic risk factor for AD. On the other hand, Seattle based Dr. Suzanne Craft reported in Madrid that intranasal delivery of insulin improved memory in early AD. The mechanism of insulin action in AD remains poorly understood. However, the results presented by Dr. Craft are very encouraging and warrant further studies. A number of studies have shown that people who used antiinflammatory drugs to treat a variety of conditions, for example rheumatoid arthritis, had a lower risk of developing AD. This observation prompted a series of clinical trials of anti-inflammatory drugs in AD. However, none have been successful. In Madrid, a group of clinical researchers from Barcelona presented interesting 8
October 2006
preliminary data with Trifusal, an anti-platelet drug that is used to prevent myocardial and cerebral infarction and that also has antiinflammatory properties. Spanish researchers reported in Madrid that this drug was somewhat effective in patients with mild cognitive impairment (MCI) and slowed the progression of this condition to AD. A series of studies by Dr. Ashley Bush from Harvard demonstrated the role of certain metals in aggregation and toxicity of Abeta peptide. His group also demonstrated a decrease in amyloid burden in model systems by compounds that interact and trap metals. Small clinical trials with a derivative of a metal trapping compound produced encouraging results. Additional positive results with new metal trapping compounds were presented in Madrid. Interesting work was pioneered several years ago by R.L. Bowen and his colleagues at the Case Western Reserve University. They showed that gonadotropins, hormones that regulate estrogen and testosterone, were elevated in patients with AD. Further studies by the group showed that these hormones increase the production of Abeta peptide. They speculated that the therapies that aim at the reduction of these hormones might be beneficial for AD patients. In Madrid the group presented results of two phase 2 studies showing promising results with anti-gonadotropin therapy. Over the years various groups have reported the association between the use of anti-oxidants and a lower risk for AD. Several direct studies have failed to show that the use of certain antioxidants, like vitamin E, can
help AD patients. However, antioxidant therapy has a great potential and it continues to attract researchers in the field. There is a real hope that within next few years we will have new therapies for AD. Dr. Dmitry Goldgaber is an active member of LIAF's Scientific Advisory Board, and Chair since 1989. In January 2005, he was nominated for a Nobel Prize in Medicine for his major breakthrough -- cloning the amyloid precursor protein (APP) gene, the first Alzheimer's gene to be identified. â??
2006 Metro Classic “The Boro vs. The Burbs� High School All Star Basketball to Benefit LIAF Sunday, October 22 Christ the King Regional H.S. 68-02 Metropolitan Avenue Middle Village, Queens Girls 4 PM - Boys 6 PM Tickets $10 at the door Call 516-767-6856
They Did It!
U.S. Olympic kayakers Kathy Colin and Dru van Hengel circumnavigated Long Island for the 6th Annual Long Island Alzheimer’s Foundation Memory Paddle Challenge. The 300-mile seven day journey helped raise awareness of Alzheimer’s disease, and about $15,000 was raised for LIAF’s critical services. The first time female team paddled 46 hours, 48 minutes, and broke the male team record from 2004 by 8 minutes. Kathy and Dru battled headwinds, high waves, currents and tides, on some days for over 9 hours. Their spirit remains strong despite sore bodies and blistered hands. To Sponsor their Strokes, call 516-767-6856. ❍
LIAFLine
Donations Antonietta Garretto
Gladys M. O'Donnell
Vera Schmidt
David Zeitlen
Rosemary Nappi
Antonia Scialli
George Zenaty
Toby Pearlstein
Bernard Geraghty
Nancy Otis
Sally Gibbons
Louise Paulson
James Joseph Sclanfari, Sr.
Eli Africk
Carole Giorgetti
Lillian Pincus
Al Seigel
Eva Baker
Emily Goldblum
Socrates Pournos
Lea Selshy
Edwin J. Baldwin
Adele Goldstein
Maria Quinones
Agnes A. Bartik
Louis B. Grilli, Sr.
Roseleen Belfiore
August Grim
Muriel & Sidney Resnick
Robert R. Bencivenga
Elizabeth Grosa
Joan Rivera
Elizabeth Groser
Elizabeth Bendernagel Roslyn Berger
Betty Hertz
Memorials In Loving Memory Of:
Honorariums In Honor Of:
Selwyn Rudnick
Jerry & Millie Shapiro
Dru van Hengel & Kathy Colin
Elaine Siev's Birthday
Sandra Shiebler Vivian Siegel
Mr. & Mrs. Jeff Blau's Wedding
Michael & Susan Warner
Cruz Maria Rosa
Peter Socci
Cynthia Decker
Jim White
Phyllis Hayden
Linda Rosen
Douglas Stonborg
Elizabeth Glazer
Mildred Herman
Marshall Rosenberg
Joseph F. Tymann
Maureen & Mike Hordy
Dr. Monroe S. Roth
Katharine Walck
Mariano Schimmenti
Eva Weisbrout
Rick Berkowitz's Father
Laura Hochron's Mother
Mildred I. Bonich
Joseph Holliday
Conchetta Bordengo
Beatrice Holst
Joan Bourgeois Donald J. Byrne James Cahill, Sr. Jennie Carcara Mildred Cardillo Raymond Cassaza Loretta Cortazzo Frances Costello Luba Cross Doris DeBatt Edmund DeCesare
Jack Judge
Donald Koenig Leonard B. Lamb Sol Lane Lucy Lartaglia Robert Lawrence Vincent Littera Rose & Vincent Loscalzo
Morris Ehrlich
Sidney Macy
Charles Eibeler
M. Maesatian
Domenico Fantozzi
Alfred Malecki
Eugen Fennell
May Martin
David Finman
Helen Mayers
Phyllis Fishkin's Mother
Jack Mazer
Martin Freeman
Sofia Milodovida
Sheldon Friedlander
Lillian Montonte
John F. Galvin III
George Walsh
Regina & Ed Joyce Eileen Katz' Birthday
Mildred Wrege
Anna King's 10th Anniversary
Bernard Zavack
Lillian Lopez
Francis Klorman
Marcia DePinna
Aida Galiano
Michael Schimmenti
Albina Vanderbeck
Mr & Mrs. Jordan Siev's Anniversary
Harold Kardonick
John A. MacDonald
Rita Murray Fruin
Emily Riggins
Carol Meinhold
Burton Morgan James Mullen Phyllis Murphy
To make a donation in memory or in honor of someone, or to celebrate a special occasion, please send your contribution to: LIAF 5 Channel Drive, Port Washington, NY 11050
A personalized tribute card will be sent tothe individual being honored or to the family of the person being memorialized. See coupon on opposite page.
LIAF Conferences & Free Workshops ■ ALL ABOUT FORGETFULNESS Tuesday, October 17 - 7:30 PM Port Washington Public Library 1 Library Drive, Port Washington ■ STRESS REDUCTION FOR THE CAREGIVER Tuesday, October 17 - 7:30 PM Bethpage Public Library 47 Powell Avenue, Bethpage ■ ALL ABOUT FORGETFULNESS Friday, October 27 - 1:00 PM Floral Park Public Library 17 Caroline Place, Floral Park ■ ALL ABOUT FORGETFULNESS Wednesday, November 1 - 3:30 PM West Babylon Public Library 211 Route 109, West Babylon ■ ALL ABOUT FORGETFULNESS Wed., November 15 - 3:00 PM New Parkway Hospital 70-35 113th Street, Forest Hills
Mary Noyalis Contact Alana Rosenstein at 516-767-6856.
10
October 2006
HELP LIAF HELP OTHERS! I Wish to Make a Donation of $_______ to LIAF
Kindly send an acknowledgment to:
(A minimum gift of $10 is suggested) Contributor Name:
Name:
Address:
Address:
City/St/Zip:
City/St/Zip:
Phone:
(LIAF sends an acknowledgment to the contributor as well)
❒ In Honor of ❒ In Memory of
Please make checks payable to: Long Island Alzheimer’s Foundation, Inc. 5 Channel Drive • Port Washington, NY 11050
Contributions to LIAF are tax-deductible to the full extent of the law. A copy of our most recent financial statement can be obtained from the NYS Office of the Attorney General, Charities Bureau, 120 Broadway, New York, NY 10271.
LIAF Product Order Form 5 Channel Drive, Port Washington, NY 11050
Newly Updated Edition Alzheimer's Directory of Services for Long Island
A Comprehensive, one-of-a-kind guide to resources and services available in Nassau, Suffolk, Brooklyn and Queens to individuals and families dealing with Alzheimer's disease and related dementias.
Publication Title
Qty
Cost
Total
Name:
About Alzheimer’s Disease
1.00
Address:
Caring For Someone With Alzheimer’s Disease
1.00
City/St/Zip:
About Choosing A Nursing Home
1.00
Telephone: (
About Entering A Nursing Home
1.00
About Paying for Nursing Home Care
1.00
About Hospice
1.00
About Dementia
1.00
Advance Medical Directives
1.00
About Do-Not-Resuscitate Orders
1.00
Life-Sustaining Treatments
1.00
Alzheimer's Directory of Services for Long Island Directory Print
50.00
Total Cost
)
Item “Caring Poster by Miriam Cassel” LIAF Cookbook Living With Alzheimer’s Video Series The Light of the Heart Meditations for Self-Healing CD by Judy Talit Guidelines to the Caregivers Audiotape
Cost 20.00 20.00 15.00
A Walk Down Memory Lane CD The 36-Hour Day When Meme Came to Live at My House Information Booklets - Total
15.00 15.00 5.00
Qty
15.00 5.00
(enter total in order form on right)
Total Cost (Prices include shipping & handling.)
Total
CHANGE SERVICE REQUESTED
NONPROFIT ORGANIZATION U.S. POSTAGE
PAID RED BANK, NJ PERMIT NO. 558
5 Channel Drive Port Washington, NY 11050
CALENDAR Upcoming Events... ■ October 22, 2006 METRO CLASSIC "THE BORO VS. THE BURBS" Christ the King Regional H.S. Middle Village ■ November 3, 2006 19TH ANNUAL REMEMBRANCE BALL The Garden City Hotel Garden City, NY ■ November 8, 2006 6TH ANNUAL CANDLE LIGHTING CEREMONY The Bristal Assisted Living North Hills
Save the Date... ■ March 22, 2007 19TH ANNUAL LIAF COPING & CARING CONFERENCE & EXPO ■ April 17, 2007 13TH ANNUAL OUTSTANDING SERVICE AWARDS LUNCHEON Garden City Hotel Garden City
13th Annual Outstanding Service Awards Luncheon April 17, 2007
Garden City Hotel, Garden City – Nomination Form – A salute to those who go above and beyond the call of duty, friendship and responsibility to the Alzheimer’s disease community. The Long Island Alzheimer’s Foundation will hold its annual spring luncheon to honor the dedicated, committed and special individuals that fuel the engines of our organizations and allow us to progress. We especially want to honor volunteers or those professionals who have gone that extra mile with exceptional service, creativity and dedication to help individuals with Alzheimer’s disease and their caregivers. Please use the nomination form to send us information on your special organization or individual. Nominations must be submitted by Wednesday, January 31, 2007, so that we may carefully consider applications and respond on a timely basis. Each awardee will receive two luncheon tickets gratis.
Suggested nominees are: • An Individual Volunteer • A Support Group Leader • A Civic-Minded Youth • A Community Service Group
• A Day Care Program • A Hospital or Nursing Home • A Community-Minded Public Official • A Health Care Professional
LIAF Nomination Name of Individual or Organization Nominated: Business Address: City, State, Zip:
Phone:
Home Address of Nominee:
Phone:
Name & Title of Person Submitting Nomination: Organization of Person Submitting Nomination: Nominator Phone #: Please summarize (250 words or less) why you are nominating this individual or organization. (Attach narrative.)